Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia

Dmitry Lioznov, Irina Amosova, Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov, Mikhail Tsyferov, Mikhail Khmelevskii, Andrei Afanasiev, Nadezhda Khomyakova, Dmitry Zubkov, Anton Tikhonov, Tao Zhu, Luis Barreto, Vitalina Dzutseva
doi: https://doi.org/10.1101/2022.03.01.22271507

Data Availability

All data produced in the present work are contained in the manuscript and supplmentary materials

Back to top
Posted March 11, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
Dmitry Lioznov, Irina Amosova, Savely A. Sheetikov, Ksenia V. Zornikova, Yana Serdyuk, Grigory A. Efimov, Mikhail Tsyferov, Mikhail Khmelevskii, Andrei Afanasiev, Nadezhda Khomyakova, Dmitry Zubkov, Anton Tikhonov, Tao Zhu, Luis Barreto, Vitalina Dzutseva
medRxiv 2022.03.01.22271507; doi: https://doi.org/10.1101/2022.03.01.22271507
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area